"100 billion bacteria in a single capsule!", "Maximum concentration!", "The higher the CFU count, the stronger the effect!"—these are common marketing claims found on probiotic packaging. They create the impression that a product's effectiveness is determined solely by the number of bacteria it contains.
However, modern evidence-based medicine tells a different story: more bacteria does not necessarily mean better results.
When evaluating a probiotic, it is important to consider not only the number of colony-forming units (CFU) but also the specific strain, its viability, its ability to reach the intestine, its mechanism of action, and the availability of high-quality clinical evidence.
What Does the CFU Count Mean?
CFU (colony-forming units) is a measure of the number of viable microorganisms in a probiotic product.
By itself, however, this value does not indicate how effective the probiotic will be.
For example, a product containing 10 billion CFU of a well-studied strain may have far greater clinical value than a product containing 100 billion bacteria whose effectiveness has never been investigated.
One Species – Different Strains, Different Properties
Even bacteria belonging to the same species can differ significantly from one another.
For example, Lacticaseibacillus rhamnosus GG and other strains of the same species have different biological properties and different levels of scientific evidence. That is why current clinical guidelines emphasize that probiotic efficacy is strain-specific.
In other words, the results obtained for one strain cannot be applied to all other bacteria of the same species.
Why Doesn't a Higher Bacterial Count Guarantee Better Results?
For a probiotic to be effective, its bacteria must:
- remain viable during manufacturing and storage;
- survive the acidic environment of the stomach;
- reach the intestine in sufficient numbers;
- interact with the gut microbiota and the immune system;
- have mechanisms of action supported by clinical research.
If even one of these conditions is not met, a very high bacterial count cannot guarantee the desired clinical outcome.
Is There a "Correct" Dose?
Effective doses vary considerably among different probiotic strains.
Some strains require only a few billion CFU per day, while others need substantially higher doses. Therefore, there is no universal bacterial count that is optimal for all probiotic products or every clinical situation.
The appropriate dosage is determined by clinical studies of the specific strain—not by the general assumption that "more is better."
How Should You Choose a Probiotic?
When selecting a probiotic, it is important to consider more than just the number of bacteria. Pay attention to the following criteria:
- the full name of the probiotic strain;
- the availability of clinical studies specifically involving that strain;
- the indications for which its effectiveness has been demonstrated;
- the recommended dosage;
- manufacturing and storage conditions;
- a guarantee that the stated number of viable bacteria is maintained until the expiration date.
These characteristics are far more important than a large number displayed on the package.
A Personalized Approach Instead of Marketing Claims
Modern personalized microbiome medicine is moving away from one-size-fits-all recommendations. The same probiotic may work differently in different individuals depending on the composition of their microbiota, overall health, diet, and the underlying condition being treated.
That is why probiotic selection should be based on scientific evidence rather than marketing claims about having "the highest number of bacteria."
Conclusion
The number of bacteria in a capsule is only one characteristic of a probiotic. It does not determine effectiveness without considering the specific strain, the available clinical evidence, and the appropriate dosage.
The modern approach is to choose probiotics with proven efficacy for a specific clinical situation rather than products that simply contain the highest CFU count.
References:
1. Hill C, Guarner F, Reid G, et al. The ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014. DOI: 10.1038/nrgastro.2014.66
2. Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nature Reviews Gastroenterology & Hepatology. 2019. DOI: 10.1038/s41575-019-0173-3
3. McFarland LV, et al. Strain-specific and disease-specific efficacy of probiotic meta-analysis. Frontiers in Medicine. 2018. DOI: 10.3389/fmed.2018.00124
4. ISAPP Consensus Panel. Expert consensus document: probiotic strain specificity and clinical application.
5. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nature Medicine. 2019. DOI: 10.1038/s41591-019-0439-x
